Back to rankings

Globe Life Inc (GL)

Undervalued
Financial ServicesInsurance - LifeUnited States

Fundamental

80

Price

$165.65

Market Cap

$12.81B

Part 1 · What the company is worth

Overview

Globe Life is a US insurance holding company that sells individual life insurance and supplemental health insurance directly to ordinary households, mostly lower- and middle-income families, through its own captive sales forces: American Income Life (which works through labor unions and affinity groups), Liberty National, Family Heritage, United American and a Direct to Consumer channel that sells by mail, television and internet. The policies are small in size — modest face amounts, modest monthly premiums — and the company's skill is in writing enormous numbers of them cheaply and keeping them on the books for decades. It does not sell to corporations, does not manage third-party money, and its annuity business is no longer a reportable segment.

How it makes money

Two streams. The first is premium: policyholders pay every month or every year, and because the health policies are generally guaranteed renewable and the life policies are permanent, the same premium tends to come back year after year with little new selling effort — in fiscal 2025 the group collected about $4.9 billion of premium. The second is investment income: the premiums arrive long before the claims are paid, so the company holds a large bond portfolio in the meantime and earns roughly $1.1 billion a year of net investment income on it. Profit on the insurance side is what management calls underwriting margin — premium minus policy benefits, minus the commissions and acquisition costs paid to the agencies; profit on the investment side is the income earned above what the policy reserves require.

Revenue by segment

Life insurance55.9%

Traditional whole life and term life policies with small face amounts, sold to individual households. American Income Life alone writes 53% of the segment's premium and the Direct to Consumer channel another 29%.

Health insurance25.4%

Generally guaranteed-renewable supplemental health cover — Medicare Supplement, cancer, critical illness, accident and other limited-benefit policies — sold to individuals. United American accounts for 44% of the segment's premium and Family Heritage for 31%.

Investment18.8%

The unit that manages the bond portfolio and cash flows backing the insurance reserves. It has no outside customers: its revenue is the net investment income earned on money the policyholders have already paid in.

Competitive moat

Cost advantage · Narrow

Globe Life's advantage is a distribution one. It owns its agencies rather than renting shelf space from brokers, and those agencies reach a customer that most life insurers find too small to serve profitably — union members, affinity-group members, households buying a few thousand dollars of cover. Writing that business at a cost per policy low enough to make money is not easily copied, and once a policy is in force it is permanent or guaranteed renewable, so the premium stream is sticky. The limit is real: the filing itself flags that these niche markets can shrink and that the company must keep recruiting and motivating agents to grow, which is a moat that has to be re-earned every year rather than one that defends itself.

What drives demand

Defensive

The in-force book barely notices the economic cycle: a whole life policy bought in 2005 keeps paying its premium in a recession, and supplemental health cover is renewed by habit. What does move with the cycle is the flow of new business and the persistency of the existing one. Globe Life's customer is the household whose budget tightens first, so in a downturn new sales slow and more policies lapse, while claims on life and supplemental health products are driven by mortality and morbidity rather than by GDP. The investment side is the other lever — a large bond portfolio means the income the company earns on its float follows interest rates, not consumer demand.

Key risks

  • The distribution network is the business — The company states that developing and maintaining its distribution channels is critical to growth, and that it must recruit and retain producing agents and keep their compensation attractive. Fewer or less productive agents means fewer new policies, whatever the demand for the product.
  • Niche markets can shrink — Life products are sold into specific niches — organized labor and affinity groups in particular, plus Direct to Consumer solicitation. Deteriorating relationships with unions or affinity organisations, or the public turning away from direct-mail and broadcast selling, would cut off sales at the source.
  • Agents are independent contractors — The filing discloses the risk that its sales agents could be reclassified as employees, with legal and tax consequences, and separately that misconduct or non-compliance by independent agents can produce litigation, regulatory findings, sanctions and monetary liability.
  • Health rate increases need a regulator's consent — Supplemental health policies are guaranteed renewable, so when claims cost more than expected the only remedy is a premium increase — and those increases must be approved by state insurance regulators, on their timetable, not the company's.
  • Actuarial assumptions can be wrong — Pricing and reserving rest on assumed mortality, morbidity and policyholder behaviour. The company discloses that deviations from those assumptions could materially harm results — a reserve set decades ago is only as good as the assumption behind it.
  • Credit and interest-rate risk in the portfolio — A large share of earnings comes from a bond portfolio exposed to market and credit risk, including downgrades and defaults, and to the level of interest rates; the most recent filing extends this disclosure to alternative assets such as limited partnerships.
  • Short-seller campaigns, litigation and reputation — Globe Life discloses short-selling strategies aimed at driving down its share price, shareholder securities litigation triggered by that volatility, and reputational damage arising from negative publicity by short sellers and from agent misconduct.

Customer concentration

There is no customer concentration to speak of and the filing discloses none: the customers are millions of individual policyholders, each paying a small premium, so no single one matters. The concentration sits on the distribution side instead — American Income Life alone produces 53% of life premium, and United American and Family Heritage together produce 75% of health premium. A problem at one agency, not the loss of a customer, is what would show up in the numbers.

The case for

Buyers argue that this is a boring machine that works: premium income that recurs by contract rather than by persuasion, a customer base too small and scattered to be fought over by larger insurers, and margins that held up in fiscal 2025 — life underwriting margin at 45% of life premium, health at 26%, net income of about $1.16 billion. They point to premium still growing (life +3%, health +9%) with net sales up 13%, to a business that funds itself and returns the surplus — 5.4 million shares repurchased for $685 million — and to a float of over a billion dollars a year in net investment income that rises as older, lower-yielding bonds mature into higher rates. The case rests on the idea that the agency model, hard to build and hard to copy, keeps producing policies for decades.

The case against

Sellers fear that the distribution engine is also the weak point. The company itself discloses that its sales agents are independent contractors who could be reclassified, that their misconduct can bring litigation and regulatory sanctions, and that negative publicity from short sellers and from agent behaviour damages the brand — allegations about sales practices in the agency channel are what has repeatedly moved the stock and triggered shareholder suits. Beyond that, sellers point to a customer base of lower-income households whose policies lapse first when money is tight, to health margins that depend on state regulators approving rate increases on time, to reserves resting on mortality and morbidity assumptions set long ago, and to earnings that lean on a bond portfolio now extended into limited partnerships and other alternative assets, where a downgrade cycle would be felt directly.

Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users

Direct competitors

Who this company fights with for the same customers

Compare

Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users

P/E: 12.1Score: 61Market cap: $56.93B

Aflac is the dominant seller of limited-benefit supplemental health cover in the United States — accident, cancer, critical illness and hospital indemnity sold at the worksite — the same policies Globe Life's Family Heritage and Liberty National agents place.

P/E: 20.4Score: 58Market cap: $14.42B

Through its Colonial Life brand, Unum competes for the same worksite voluntary-benefit enrolments, offering employees accident, critical illness and supplemental life cover paid by payroll deduction.

CNO Financial Group, Inc.CNO

CNO sells the same middle-income and senior products Globe Life lives on — Medicare Supplement, worksite supplemental health and direct-marketed final expense life — through career agents and direct mail, and its own 10-K names Globe Life's subsidiaries as competitors.

Primerica, Inc.PRI

Primerica sells term life to middle-income American and Canadian households through a large force of exclusive, part-time agents recruited from the same communities, which is the model of Globe Life's American Income Life and Liberty National channels.

Mutual of Omaha Insurance CompanyNot tracked

Mutual of Omaha is one of the largest writers of Medicare Supplement policies and of direct-marketed final expense life insurance for older buyers, competing head-on with Globe Life's United American and Direct to Consumer channels.

Balance Sheet & Liquidity

Revenue

$6.19B

Trailing 12 months (through 6/30/2026)

Net Income

$1.21B

Trailing 12 months (through 6/30/2026)

Free Cash Flow

$1.25B

Total Equity

$5.97B

Total Liabilities

$24.84B

Current Ratio

0.66

Interest Coverage

-

Debt/EBITDA

1.75

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

InsuranceUndervalued

Fair Value

$223.58

Current Price

$165.65

Margin of Safety

+25.9%

Fair Value Range

$145.33 - $301.84

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$193.91
Discounted cash flow (DCF):Not applicable to this type of company
Earnings multiple (P/E):$156.51
Graham growth formula:Not applicable to this type of company
Earnings power value (EPV):Not applicable to this type of company
Justified P/B:$307.44
Dividend discount (Gordon):$27.45
P/FFO, funds from operations:Not applicable to this type of company
Mid-cycle earnings:Not applicable to this type of company
Revenue multiple:Not applicable to this type of company
Analyst Consensus:Buy (18B / 5H / 0S)
Last Earnings Surprise:-4.66%

Valuation Metrics

P/E Ratio

11.01

ROE

19.4%

P/B Ratio

2.07

P/FCF

10.33

Gross Margin

-

ROIC

-

Profitability Radar

Value Creation (Economic Moat)

ROIC

-

WACC

7.2%

ROIC − WACC

-

Fundamental Analysis Criteria

Passed (18)

  • EPS shows upward trend
  • EPS CAGR 5.36%
  • Price CAGR 8.78%
  • P/FCF 10.33
  • P/B Ratio 2.07
  • Positive Free Cash Flow
  • CapEx intensity
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Undervalued)
  • ROE 20.3%
  • Analyst Consensus 78% Buy
  • PEG Ratio 0.68
  • Earnings Quality (OCF/NI) 1.15
  • Share Dilution -8.0%
  • Net Margin Trend 19.6% vs 18.1%
  • Piotroski F-Score 6/9

Failed (4)

  • Debt/Equity ratio
  • Price below Graham Number
  • Revenue Growth 5Y 4.8%
  • Earnings Surprise avg -2.6%

Unavailable (6)

  • ROIC NaN%
  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Current Ratio
  • Interest Coverage

Piotroski F-Score

6/9

Mixed signals: some areas need attention

score
criteria

Earnings Quality

1.15

High quality: earnings backed by cash

Share Dilution

-8.0%

Buying back shares. Shareholder friendly

Institutional Holdings

Governance

Executive Team

NameTitleAge
Mr. Frank Martin SvobodaCo-Chairman & Co-CEO63
Mr. James Matthew DardenCo-Chairman & Co-CEO54
Mr. Thomas Peter KalmbachExecutive VP & CFO60
Mr. Robert Edward HensleyExecutive VP & Chief Investment Officer57
Mr. Robert Brian Mitchell J.D.Executive VP, General Counsel & Chief Risk Officer61
Mr. Michael Clay MajorsExecutive VP & Chief Strategy Officer62
Mr. M. Shane HenrieCorporate Senior VP & Chief Accounting Officer51
Mr. Christopher Kyle TylerExecutive VP & Chief Information Officer51
Ms. Dolores L. SkarjuneExecutive VP & Chief Administrative Officer59
Mr. Stephen MotaVice President of Investor Relations-

Audit Risk

2

Board Risk

6

Compensation Risk

9

Shareholder Rights Risk

3

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-25

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-08-05

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-08-07

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Latest News

Recent headlines for GL, sourced from Markets Gazette.

No recent news for GL.